Post from IHUB by falconer66a, Fletch falcon
Post# of 1460
(Total Views: 432)
Posted On: 10/26/2021 6:22:25 PM
Post from IHUB by falconer66a,
Fletch
falconer66a Tuesday, 10/26/21 05:57:28 PM
Re: GD post# 333828 0
Post # of 333841
Is there a “competition” factor with blarcamesine?
Quote:
Two of 2-73's competitors, NVS RTT gene therapy and CRTX's ALD drug, are gone today.
If someone would, please detail how any “competing” new drugs or procedures for any of the CNS diseases Anavex is targeting with blarcamesine can possibly effect the AVXL share price.
What’s this ‘competition’ business? Doesn’t make sense. Blarcamesine’s only ‘competition’ is Aricept, an existing Alzheimer’s drug. To gain FDA sales and use approval, blarcamesine (in the ongoing clinical trial) must prove to be at least as safe and at least as effective as Aricept. What other drugs are, or might be in competition?
Are some presuming that there are only limited funds available to invest in companies with promising new drugs, so therefore blarcamesine (and Anavex) might lose out with other new drugs gaining FDA approval?
The only thing that counts is how well a new drug works in real patients. If it works well (as will be the case with blarcamesine) there is no competitive factor whatsoever. Both retail and institutional equity investors will direct their funds to the company with the best drug; regardless of other “competing” drugs. In this case, to Anavex Life Sciences Corp (AVXL).
No other company, with any other new or existing drug, has come close to both the safety and therapeutic efficacies blarcamesine has demonstrated in both pre-clinical murine (lab rodent) trials and also in early-stage human trials. No other drug possesses or utilizes the unique mechanism of action (MOA) of blarcamesine; propitious sigma-1 receptor protein activation.
Bring ‘em on, them ‘competitors.’ They will lose. When the final blarcamesine trial results appear for the three definitive human trials (Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s disease), the equity market will understand them and appropriately respond. Competitors (should there be any) will be left in the dust. Blarcamesine will pull away right at the gate....
Fletch
falconer66a Tuesday, 10/26/21 05:57:28 PM
Re: GD post# 333828 0
Post # of 333841
Is there a “competition” factor with blarcamesine?
Quote:
Two of 2-73's competitors, NVS RTT gene therapy and CRTX's ALD drug, are gone today.
If someone would, please detail how any “competing” new drugs or procedures for any of the CNS diseases Anavex is targeting with blarcamesine can possibly effect the AVXL share price.
What’s this ‘competition’ business? Doesn’t make sense. Blarcamesine’s only ‘competition’ is Aricept, an existing Alzheimer’s drug. To gain FDA sales and use approval, blarcamesine (in the ongoing clinical trial) must prove to be at least as safe and at least as effective as Aricept. What other drugs are, or might be in competition?
Are some presuming that there are only limited funds available to invest in companies with promising new drugs, so therefore blarcamesine (and Anavex) might lose out with other new drugs gaining FDA approval?
The only thing that counts is how well a new drug works in real patients. If it works well (as will be the case with blarcamesine) there is no competitive factor whatsoever. Both retail and institutional equity investors will direct their funds to the company with the best drug; regardless of other “competing” drugs. In this case, to Anavex Life Sciences Corp (AVXL).
No other company, with any other new or existing drug, has come close to both the safety and therapeutic efficacies blarcamesine has demonstrated in both pre-clinical murine (lab rodent) trials and also in early-stage human trials. No other drug possesses or utilizes the unique mechanism of action (MOA) of blarcamesine; propitious sigma-1 receptor protein activation.
Bring ‘em on, them ‘competitors.’ They will lose. When the final blarcamesine trial results appear for the three definitive human trials (Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s disease), the equity market will understand them and appropriately respond. Competitors (should there be any) will be left in the dust. Blarcamesine will pull away right at the gate....
(0)
(0)